ProCE Banner Activity

How I’m Adapting My Frontline DLBCL Approaches Based on Recent Advances

Clinical Thought
In this commentary, I will address how diffuse large B cell lymphoma looks at presentation, discuss how current frontline treatment varies among patient subgroups, and review recent data supporting polatuzumab vedotin plus R-CHP as an improvement vs R-CHOP.

Released: March 03, 2022

Expiration: March 02, 2023

No longer available for credit.

Share

Faculty

Brad S. Kahl

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Brad S. Kahl, MD

Skoronski Chair of Lymphoma Research
Associate Director for Clinical Research
UW Carbone Cancer Center
University of Wisconsin School of Public Health
Madison, Wisconsin

Brad S. Kahl, MD, has disclosed that he has received funds for research support from AbbVie, ADCT, AstraZeneca, BeiGene, and Genentech and consulting fees from AbbVie, Adaptive, ADCT, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Incyte, Janssen, Karyopharm, Kite, MEI, Pharmacyclics, Roche, and Teva.